Catabasis Pharmaceuticals Inc. (Nasdaq: CATB) published positive results from a Phase 1 study of its Duchenne muscular dystrophy treatment edasalonexent in the Journal of Clinical Pharmacology. Shares of the biopharmaceutical gained 82 cents to close at $4.97.